A pharmaceutical composition for use in preventing or treating hepatitis, hepatic fibrosis, or hepatic cirrhosis; wherein the pharmaceutical composition contains, as an effective component, a fusion protein comprising: a fibroblast growth factor 21 (FGF21) mutant protein, an Fc region of an immunoglobulin, and a biologically active protein; wherein the FGF21 mutant protein comprises at least one mutation selected from the group consisting of the following mutations: a substitution of amino acids at positions 98 to 101 from the N-terminus of a wild-type FGF21 protein with an amino acid sequence of EIRP (SEQ ID NO: 68), a substitution of amino acids at positions 170 to 174 from the N-terminus of a wild-type FGF21 protein with an amino acid sequence of TGLEAV (SEQ ID NO: 69), a substitution of amino acids at positions 170 to 174 from the N-terminus of a wild-type FGF21 protein with an amino acid sequence of TGLEAN (SEQ ID NO: 70), and a substitution of an amino acid at position 174 from the N-terminus of a wild-type FGF21 protein with an amino acid N; wherein the wild-type FGF21 protein has an amino acid sequence represented by SEQ ID NO: 1; wherein said hepatitis is selected from the group consisting of acute viral hepatitis, chronic hepatitis, alcoholic hepatitis, autoimmune hepatitis and fulminant hepatitis; and wherein the biologically active protein is one selected from GLP-1 and a mutant thereof having an amino acid sequence represented by any one of SEQ ID NOs: 43 to 46. wherein the pharmaceutical composition contains, as an effective component, a fusion protein comprising: a fibroblast growth factor 21 (FGF21) mutant protein, an Fc region of an immunoglobulin, and a biologically active protein; wherein the FGF21 mutant protein comprises at least one mutation selected from the group consisting of the following mutations: a substitution of amino acids at positions 98 to 101 from the N-terminus of a wild-type FGF21 protein with an amino acid sequence of EIRP (SEQ ID NO: 68), a substitution of amino acids at positions 170 to 174 from the N-terminus of a wild-type FGF21 protein with an amino acid sequence of TGLEAV (SEQ ID NO: 69), a substitution of amino acids at positions 170 to 174 from the N-terminus of a wild-type FGF21 protein with an amino acid sequence of TGLEAN (SEQ ID NO: 70), and a substitution of an amino acid at position 174 from the N-terminus of a wild-type FGF21 protein with an amino acid N; wherein the wild-type FGF21 protein has an amino acid sequence represented by SEQ ID NO: 1; wherein said hepatitis is selected from the group consisting of acute viral hepatitis, chronic hepatitis, alcoholic hepatitis, autoimmune hepatitis and fulminant hepatitis; and wherein the biologically active protein is one selected from GLP-1 and a mutant thereof having an amino acid sequence represented by any one of SEQ ID NOs: 43 to 46. a substitution of amino acids at positions 98 to 101 from the N-terminus of a wild-type FGF21 protein with an amino acid sequence of EIRP (SEQ ID NO: 68), a substitution of amino acids at positions 170 to 174 from the N-terminus of a wild-type FGF21 protein with an amino acid sequence of TGLEAV (SEQ ID NO: 69), a substitution of amino acids at positions 170 to 174 from the N-terminus of a wild-type FGF21 protein with an amino acid sequence of TGLEAN (SEQ ID NO: 70), and a substitution of an amino acid at position 174 from the N-terminus of a wild-type FGF21 protein with an amino acid N; wherein the wild-type FGF21 protein has an amino acid sequence represented by SEQ ID NO: 1; wherein said hepatitis is selected from the group consisting of acute viral hepatitis, chronic hepatitis, alcoholic hepatitis, autoimmune hepatitis and fulminant hepatitis; and wherein the biologically active protein is one selected from GLP-1 and a mutant thereof having an amino acid sequence represented by any one of SEQ ID NOs: 43 to 46. <EOS>